Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
CSPC will receive an upfront payment of $100 million from AstraZeneca
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Poor oral health (periodontal disease) impacts nearly 51% of Indians
India has taken the lead in recognising NAFLD as a major non-communicable disease
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
